Poster endorsement? It was peer review medical publication. A CR on such low dosage so early in Ph1 is very rare where even @Mason14 said was excellent result and tried to discredit it by saying IMU then increase the dosage as management weren't seeing enough efficacy despite stating he is a "scientist" who is supposedly meant to know how Ph1 clinical trial are conducted for OBD.
IMU is the pick because of the potential in the next 8-12 months, I'm not sure what you mean by "murky combo treatment", a lot of new cancer treatment on clinical trial are in combination with approved cancer drug to find a better effective cancer treatment.
Why IMU is a multi multi bagger, page-24370
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
0.001(0.98%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.2¢ | 5.1¢ | $105.0K | 2.056M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 470321 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 850276 | 9 |
View Market Depth
| Last trade - 10.51am 04/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |